Aprogen
에이프로젠 · 007460
Health Care Pharmaceuticals · KOSPI
Market cap US$55.6M (₩76.7B)
Overview
Aprogen is a diversified Korean company whose activities span biopharmaceuticals, including biosimilar and therapeutic-protein drugs for autoimmune diseases and cancer, alongside industrial businesses such as hardfacing alloys, steel distribution, thermal insulation, and geothermal and fuel-cell energy systems.
Its biopharmaceutical unit develops and produces protein-based medicines using humanized-antibody engineering and cell-culture technologies, while subsidiary Aprogen Biologics focuses on manufacturing and supplying those biopharmaceutical products. Listed on KOSPI, Korea's main stock exchange, the company operates across several largely unrelated business lines through a network of consolidated subsidiaries.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$109.1M
- FY2024US$108.8M
- FY2025US$85.5M
Operating profit
- FY2023−US$64.4M
- FY2024−US$62.9M
- FY2025−US$69.3M
Net income
- FY2023−US$70.5M
- FY2024−US$72.7M
- FY2025−US$101.9M
Key ratios (FY2025)
Why it matters
The biopharmaceutical business was absorbed into Aprogen through a merger with a previously separate entity, and a subsidiary called Entootech also operates within the group making semiconductor-equipment components.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?